Overview

A Trial Evaluating the Effectiveness of Contrave in Patients Who Have Weight Recidivism Following Bariatric Surgery

Status:
Not yet recruiting

Trial end date:
2023-05-15

Target enrollment:

Participant gender:

Summary

Contrave (naltrexone HCl and bupropion HCl) extended-release tablet is an approved drug and indicated to be used with a low calorie diet and increased physical activity for chronic weight management in obese adults (BMI 30 Kg/m2 or greater) or overweight adults (BMI 27 Kg/m2 or greater) with at least one weight related condition such as hypertension or diabetes. It is unknown how many or which medical treatments for weight loss, such as Contrave work in the subjects who have had bariatric surgery. The purpose of this study is to explore the effectiveness of Contrave combined with usual care (dietary and behaviour counselling) compared to placebo with usual care, in patients who have inadequate weight loss or significant weight regain following bariatric surgery.

Phase:

Phase 4

Details

Lead Sponsor:

St. Joseph's Healthcare Hamilton

Collaborator:

Bausch Health, Canada Inc.

Treatments:

Bupropion
Bupropion hydrochloride, naltrexone hydrochoride drug combination
Naltrexone